Zacks Small Cap Predicts Cytosorbents Q1 Earnings

Cytosorbents Co. (NASDAQ:CTSO) – Stock analysts at Zacks Small Cap issued their Q1 2025 earnings estimates for shares of Cytosorbents in a research note issued to investors on Friday, April 4th. Zacks Small Cap analyst T. Kerr expects that the medical research company will post earnings per share of ($0.08) for the quarter. The consensus estimate for Cytosorbents’ current full-year earnings is ($0.30) per share. Zacks Small Cap also issued estimates for Cytosorbents’ Q2 2025 earnings at ($0.06) EPS.

A number of other equities analysts also recently commented on CTSO. HC Wainwright reiterated a “neutral” rating and issued a $1.00 target price on shares of Cytosorbents in a report on Thursday, April 3rd. D. Boral Capital reissued a “buy” rating and set a $10.00 target price on shares of Cytosorbents in a research report on Tuesday, April 1st. Finally, StockNews.com assumed coverage on shares of Cytosorbents in a report on Thursday, April 3rd. They issued a “hold” rating on the stock. Two analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $4.67.

Cytosorbents Trading Down 3.0 %

CTSO opened at $0.96 on Monday. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06. The firm has a market cap of $60 million, a price-to-earnings ratio of -2.67 and a beta of 1.17. Cytosorbents has a 12 month low of $0.70 and a 12 month high of $1.61. The stock has a fifty day moving average price of $1.06 and a 200-day moving average price of $1.03.

Cytosorbents (NASDAQ:CTSO) last issued its quarterly earnings data on Monday, March 31st. The medical research company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.04. The company had revenue of $9.20 million for the quarter, compared to analyst estimates of $10.09 million. Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 118.54%.

Institutional Trading of Cytosorbents

A number of institutional investors have recently bought and sold shares of CTSO. Geode Capital Management LLC increased its stake in Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after purchasing an additional 32,415 shares in the last quarter. Skylands Capital LLC grew its holdings in shares of Cytosorbents by 1.0% during the fourth quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company’s stock valued at $2,531,000 after buying an additional 26,195 shares during the last quarter. Millennium Management LLC acquired a new position in shares of Cytosorbents in the 4th quarter valued at $30,000. Northern Trust Corp raised its stake in Cytosorbents by 22.3% in the 4th quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock worth $83,000 after acquiring an additional 16,701 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Cytosorbents during the 4th quarter worth about $99,000. 32.87% of the stock is currently owned by institutional investors and hedge funds.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.